A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease

Krishna K. Pudi¹, Chris N. Barnes², Edmund J. Moran², Brett Haumann³* and Edward Kerwin⁴

Abstract

Background: Revefenacin is a once-daily long-acting muscarinic antagonist (LAMA) in clinical development for the treatment of patients with chronic obstructive pulmonary disease (COPD). In a dose-ranging study, nebulized once-daily revefenacin had a long duration of action in patients after 7 days' administration of doses up to 700 μg. In this multiple-dose study, the bronchodilation efficacy and adverse events profile were characterized in patients administered nebulized revefenacin once daily for 28 days.

Methods: A total of 355 COPD patients (mean age 62 years, mean forced expiratory volume in 1 s [FEV₁] 44% of predicted) were randomized in a double-blind, placebo-controlled parallel group study. Inhaled corticosteroids as well as short-acting bronchodilators were permitted. Once-daily treatments (44, 88, 175 or 350 μg revefenacin or matching placebo) were administered by a standard jet nebulizer, for 28 days. The primary endpoint was change from baseline in D28 trough FEV₁, and secondary endpoints included weighted mean FEV₁ over 0 to 24 h and rescue medication (albuterol) use. Safety evaluations included adverse events, laboratory assessments, electrocardiograms and 24-h Holter profiles.

Results: Revefenacin (88, 175 and 350 μg) significantly improved D28 trough FEV₁ over placebo (187.4, 166.6 and 170.6 mL, respectively, all \( p < 0.001 \)); 44 μg produced a sub-therapeutic response. At doses ≥88 μg, more than 80% of patients achieved at least a 100-mL increase from baseline FEV₁ in the first 4 h post dose compared with 33% of placebo patients. For doses ≥88 μg, D28 24 h weighted mean differences from placebo for FEV₁ were numerically similar to respective trough FEV₁ values, indicating bronchodilation was sustained for 24 h post dose. Doses ≥88 μg reduced the average number of albuterol puffs/day by more than one puff/day. The 350 μg dose did not demonstrate additional efficacy over that observed with 175 μg revefenacin. Revefenacin was generally well tolerated, with minimal reports of systemic anti-cholinergic effects.

Conclusions: These data suggest that 88 and 175 μg revefenacin are appropriate doses for use in longer-term safety and efficacy trials. Revefenacin offers the potential for the first once-daily LAMA for nebulization in patients with COPD who require or prefer a nebulized drug delivery option.

Trial registration: ClinicalTrials.gov NCT02040792. Registered January 16, 2014.
Background

Long-acting inhaled bronchodilators are recommended as maintenance therapy for chronic obstructive pulmonary disease (COPD) patients with moderate to severe symptoms or those who are at high risk for COPD exacerbations [1]. These bronchodilators fall into two classes: long-acting muscarinic antagonists (LAMAs) and long-acting beta agonists (LABAs), with the once-daily LAMA, tiotropium, and the twice-daily LABAs, salmeterol and formoterol, being the most widely prescribed for COPD [2–4]. Moreover, monotherapy with a LAMA is considered a first-line therapy option for many patients with moderate to severe COPD [1, 5].

Long-acting inhaled bronchodilators are most often self-administered with hand-held devices such as pressurized metered-dose inhalers or dry powder inhalers [6, 7]. Some patients, however, have difficulty using hand-held devices (eg, the elderly or cognitively impaired) [8, 9], which can result in inaccurate dosing, poor adherence and potentially poor clinical outcomes [10–12]. Nebulizers, which are easy to use and offer similar efficacy [8, 13], are an alternative to hand-held devices. Yet there are limited options for maintenance treatment with nebulized long-acting bronchodilators. Nebulized LABAs (Brovana® [arformoterol tartrate] and Perforomist® [formoterol fumarate]) are currently available; however, these agents are labelled for twice-daily administration. Thus, despite the ascendancy of effective and convenient once-daily LAMA bronchodilator therapy (tiotropium bromide) in clinical practice for both reversal of bronchoconstriction and control of acute exacerbations of COPD, and the recent emergence of additional once-daily LAMA, LABA/ICS and LAMA/LABA handheld products, no once-daily nebulized bronchodilator has been available to patients who require or prefer nebulized drug delivery [9]. Revefenacin is the first once-daily anti-muscarinic administered via a standard jet nebulizer to enter late-stage clinical development [9, 14, 15].

Research has shown that revefenacin may produce sustained, long-acting bronchodilation similar to tiotropium bromide but with a lower potential for anti-muscarinic side effects (eg, dry mouth) [16]. In a randomized, double blind, repeat dose, placebo-controlled dose-ranging study, nebulized revefenacin (22 to 700 μg administered for 7 days via a standard jet nebulizer) demonstrated a long duration of action and low systemic exposure in patients with COPD [17]. Moreover, doses 88 μg and above produced clinically effective bronchodilation as measured by trough forced expiratory volume in 1 s (FEV₁) and serial spirometric assessments following the D7 dose [17]. The objective of this 28-day study was to identify appropriate revefenacin doses for longer-term safety and efficacy trials in patients with COPD.¹

Methods

Study design and conduct

This randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study, conducted at 41 centers in the United States between April 2014 and July 2014, evaluated the efficacy, safety and tolerability of revefenacin in patients with COPD (ClinicalTrials.gov NCT02040792). The study conformed to appropriate ethical guidelines and was conducted in accordance with the principles of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guideline for good clinical practice [18] and the code of ethics of the World Medical Association’s Declaration of Helsinki [19], with all patients providing written informed consent.

Patients and treatments

Patients were men or women of non-childbearing potential (aged 40 to 75 years) with moderate to severe COPD [1] and a current or former smoking history of more than 10 pack-years, who at screening demonstrated a post-ipratropium bromide ratio of FEV₁/forced vital capacity of <0.7 and a FEV₁ of 30–80% of the predicted normal value after withholding short-acting bronchodilators for ≥6 h and long-acting bronchodilators for ≥14 days. In addition, patients were eligible for enrollment regardless of the numerical improvement in their FEV₁ following bronchodilator (ipratropium bromide and/or albuterol) administration via a PARI LC® Sprint nebulizer (PARI, Midlothian, Virginia, US) at screening. Patients who demonstrated reversibility to placebo (≥12% change and ≥200 mL) were excluded from the study.

Following the screening period (two or three visits no more than 50 days prior to D1 of the treatment period), patients were stratified at randomization based on responsiveness status to ipratropium bromide during screening (responsive or non-responsive, with responsiveness defined as ≥12% and ≥200 mL change in FEV₁ 45 min after completion of ipratropium bromide nebulization). Randomized patients received a 3-mL inhalation solution of placebo or revefenacin (44, 88, 175 or 350 μg) administered once daily for 28 days from a PARI LC Sprint nebulizer. Dosing occurred in the morning and was self-administered, except on D15, D16 and D28, when patients were dosed at their clinical study center.

All study personnel, as well as the sponsor, site monitors and patients, were blind to treatment allocation throughout the study.

Concomitant therapy was managed during the study as follows: LABA and LAMA bronchodilators were prohibited; combination steroid and LABA therapy was discontinued and the steroid component was replaced with an equivalent strength steroid inhaler monotherapy. Albuterol was allowed as necessary but was requested to
be withheld for 6 h before the initial spirometry assessment performed at each study visit and during the course of the entire visit when serial spirometry was performed (unless medically necessary).

**Assessments and endpoints**

For FEV₁ assessment, spirometry was performed according to techniques consistent with the American Thoracic Society guidelines for spirometry [20] and conducted at specified time points during the screening visits and treatment period (D1 baseline [45 min and 15 min predose; 0 to 6 h postdose]; D15, D16 and D28 pretreatment trough [45 min and 15 min predose]; and D28/29 post treatment [0 to 24 h]). Peak expiratory flow rate (PEF) was conducted by the participants each morning and evening throughout the treatment period and up to the post-treatment follow-up visit. Safety and tolerability were assessed based on adverse events (AEs), clinical laboratory findings, vital signs, physical examinations and/or electrocardiogram (ECG) readings obtained before, during and after the treatment period. A diary was used for recording dosing times, rescue medication use, concomitant medications and AEs throughout the 28-day dosing period and the 1-week follow-up period.

The primary endpoint was change from baseline in D28 trough FEV₁ (the mean of the 23.25-h and 23.75-h 28-day dosing period and the 1-week follow-up period. The intent-to-treat (ITT) population was used for all efficacy analyses and included all participants who were randomized into the study and received at least one dose of study drug. The primary endpoint was analyzed using a repeated measures model, incorporating treatment group, smoking status, responsiveness to ipratropium bromide and/or albuterol, age (<65 years or ≥65 years) and sex as fixed effect class terms and a continuous covariate for baseline FEV₁. A random effect for subject and a time effect (D15, D16, D28 and D29) were also included in the model. Least squares (LS) means and 95% confidence intervals (CIs) were calculated for the differences between each revefenacin dose and placebo on the primary endpoint, and statistical significance of pairwise comparisons were evaluated using the Benjamini-Hochberg step-up adjustment for multiple comparisons for the primary endpoint. A similar analysis methodology was used to assess the secondary spirometry endpoints and rescue medication use with no adjustment for multiplicity.

PK data were analyzed using summary statistics for all patients who provided PK data for at least one dose of revefenacin. Key PK parameters calculated included the time to maximum plasma concentration (tₘₐₓ), the maximum plasma concentration (Cₘₐₓ), area under the (AUC) plasma concentration-time curve from time 0 to 24 h (AUC₀₋₂₄) and from time 0 to the last detectable time point (AUC₀₋₉) and terminal elimination half-life (t₁/₂).

The safety population was used for all safety analyses and included all subjects who were randomized into the study and received at least one dose of study drug.

**Results**

**Patients**

In total, 355 patients were enrolled in the study (Fig. 1). One patient, identified as participating in another clinical study, was removed from the ITT population (N = 354) but retained in the safety population (N = 355). One patient receiving revefenacin 350 μg was removed from the study on D6 due to a non-treatment—emergent prolonged QTcF adverse event (QTcF, >500 msc) revealed during the screening ECG but not reviewed by the investigator until post first dose. That subject is included in both the ITT and safety populations though the prolonged QTcF adverse event is not contained in the treatment-emergent AE summaries.

Patient demographics and key baseline characteristics, which were similar between treatment groups, are summarized in Table 1.

**Efficacy**

The primary endpoint, change from baseline in D28 trough FEV₁, demonstrated significant benefit with revefenacin...
μcant and likely sub-therapeutic improvement was noted in FEV1 (LS mean [95% CI], 187.4 [118.8, 256.1] mL; placebo noted for all doses (Table 2). Additionally, for doses ≥88 µg on D28, differences from placebo for both weighted mean FEV1(0–24h) and FEV1(10–24h) values were numerically similar to respective trough FEV1 values, suggesting sustained 24-h bronchodilation.

Revefenacin decreased albuterol rescue inhaler use compared with placebo for the three highest doses. On average, placebo subjects used three puffs/day of rescue albuterol (Fig. 4a). Doses ≥88 µg significantly decreased rescue medication use by a clinically relevant decrease of at least one puff per day in a dose-dependent manner (p < 0.005). Expressed as rescue inhaler-free days over the entire treatment period, revefenacin 175 µg and 350 µg increased the number of rescue-free days over placebo by ≥14% (p < 0.05; Fig. 4b), corresponding to an increase of approximately one rescue-free day per week.

Throughout the 28-day study period, revefenacin produced sustained increases in morning and evening PEF (Fig. 5); PEF measurements reached steady state early in dosing, prior to D7, and were maintained throughout the remaining evaluation period. For revefenacin doses ≥88 µg, LS mean placebo-adjusted increases in AM and PM PEF showed clinically relevant improvements of approximately 27 L/min and 29 L/min, respectively. In
Table 1 Baseline demographics and clinical characteristics (ITT population)

|                         | Placebo (n = 70) | Revefenacin 44 μg (n = 68) | Revefenacin 88 μg (n = 71) | Revefenacin 175 μg (n = 71) | Revefenacin 350 μg (n = 74) | Total (N = 354) |
|-------------------------|------------------|----------------------------|---------------------------|-----------------------------|-----------------------------|-----------------|
| Age (years)             |                  |                            |                           |                             |                             |                 |
| Mean (SD)               | 62.2 (9.17)      | 60.9 (8.87)                | 60.4 (7.98)               | 64.5 (7.69)                 | 61.4 (8.98)                 | 61.9 (8.63)     |
| Sex (%)                 |                  |                            |                           |                             |                             |                 |
| Male                    | 37 (52.9)        | 32 (47.1)                  | 32 (45.1)                 | 37 (52.1)                   | 40 (54.1)                   | 178 (50.3)      |
| Female                  | 33 (47.1)        | 36 (52.9)                  | 39 (54.9)                 | 34 (47.9)                   | 34 (45.9)                   | 176 (49.7)      |
| Race (%)                |                  |                            |                           |                             |                             |                 |
| White                   | 65 (92.9)        | 63 (92.6)                  | 64 (90.1)                 | 65 (91.5)                   | 67 (90.5)                   | 324 (91.5)      |
| Black/African American  | 4 (5.7)          | 4 (5.9)                    | 6 (8.5)                   | 5 (7.0)                     | 6 (8.1)                     | 25 (7.1)        |
| Other                   | 1 (1.4)          | 1 (1.5)                    | 1 (1.4)                   | 1 (1.4)                     | 1 (1.4)                     | 5 (1.4)         |
| BMI (kg/m²)             |                  |                            |                           |                             |                             |                 |
| Mean (SD)               | 27.6 (5.73)      | 27.9 (6.87)                | 27.0 (5.92)               | 28.0 (5.30)                 | 29.0 (5.76)                 | 27.9 (5.93)     |
| Current smoker (%)      |                  |                            |                           |                             |                             |                 |
| Yes                     | 35 (50.0)        | 40 (58.8)                  | 44 (62.0)                 | 33 (46.5)                   | 38 (51.4)                   | 190 (53.7)      |
| Smoking duration (pack-years) | 38.2 (9.71) | 39.3 (11.59)               | 38.9 (10.16)              | 41.2 (10.01)                | 39.6 (9.04)                 | 39.5 (10.11)    |
| Current ICS use (%)     |                  |                            |                           |                             |                             |                 |
| Yes                     | 29 (41.4)        | 25 (36.8)                  | 24 (33.8)                 | 26 (36.6)                   | 26 (35.1)                   | 130 (36.7)      |
| Pre-dose FEV₁ (mL)      |                  |                            |                           |                             |                             |                 |
| Mean (SD)               | 1205.0 (473.00)  | 1279.0 (470.10)            | 1321.0 (441.58)           | 1267.2 (415.67)             | 1338.8 (483.95)             | 1282.6 (457.25) |
| Pre-dose FEV₁/FVC (%)   |                  |                            |                           |                             |                             |                 |
| n                       | 70               | 68                         | 71                        | 71                          | 72                          | 352             |
| Mean (SD)               | 0.50 (0.11)      | 0.51 (0.11)                | 0.52 (0.09)               | 0.51 (0.10)                 | 0.52 (0.09)                 | 0.51 (0.10)     |
| Percent predicted post-bronchodilator FEV₁ (%) |                  |                            |                           |                             |                             |                 |
| n                       | 70               | 68                         | 71                        | 71                          | 72                          | 352             |
| Mean (SD)               | 41.2 (13.00)     | 43.0 (13.35)               | 45.1 (12.43)              | 44.0 (11.76)                | 44.5 (12.35)                | 43.6 (12.58)    |

Abbreviations: BMI body mass index, FEV₁ forced expiratory volume in 1 s, FVC forced vital capacity, ICS inhaled corticosteroid, ITT intent to treat, SD standard deviation

contrast, the PEF response for revefenacin 44 μg fell below that of the other doses for the majority of the evaluation period.

Pharmacokinetics

Plasma concentration data were received and analyzed for 34 subjects treated with revefenacin 44, 88, 175 or 350 μg for 28 days. Median tmax values ranged from 0.483 to 0.517 h and mean Cmax values ranged from 0.0203 to 0.146 ng/mL (Table 3). After reaching maximum concentrations, revefenacin concentrations declined rapidly in a biphasic manner and were followed by a slow apparent terminal elimination phase characterized by mean t1/2 values of 51.9 and 57.9 h at the 175- and 350-μg dose levels, respectively. Mean AUC0–24 values ranged from 0.0347 to 0.365 ng·hr./mL, and mean AUC0–t values ranged from 0.0299 to 0.724 ng·hr./mL. Relative to the 44 μg dose, mean Cmax and AUC values increased with the increases in dose level. Conclusions with respect to dose proportionality were not drawn in this study due to the high variability and limited sample size in each dose group.

Safety

Of the 355 patients in the safety population, 328 (92.4%) completed the study per protocol. Twelve of 355 subjects (3.4%) had an AE that led to permanent treatment discontinuation, which occurred more frequently in the two highest-dose revefenacin treatment groups (7.0% [n = 71] and 5.4% [n = 74] in the 175 μg and 350 μg groups, respectively) than in the other treatment groups (1.4% [n = 71], 1.5% [n = 68] and 1.4% [n = 71] in the placebo and revefenacin 44 μg and 88 μg groups, respectively). With the exception of one event of respiratory distress experienced by a placebo patient, all events resolved.
Table 2 Summary of key spirometric measurements (ITT population)

|                      | Placebo | Revefenacin |
|----------------------|---------|-------------|
|                      |         | 44 µg | 88 µg | 175 µg | 350 µg |
| D28\textsuperscript{a} trough FEV\textsubscript{1} change from baseline, mL |         |       |       |       |       |
| n                    | 55      | 60    | 63    | 59     | 63     |
| LS mean (SE)         | −32.4 (25.36) | 19.4 (24.98) | 155.0 (24.61) | 134.2 (25.07) | 138.2 (24.38) |
| LS mean difference from placebo (95% CI) | NA | 51.8 (−17.3, 121.0) | 187.4 (118.8, 256.1)** | 166.6 (97.3, 236.0)** | 170.6 (101.9, 239.3)** |
| D1 weighted mean FEV\textsubscript{1}(0–6h), mL |         |       |       |       |       |
| n                    | 69      | 66    | 68    | 70     | 70     |
| LS mean (SE)         | 33.3 (15.93) | 145.1 (16.57) | 193.8 (16.42) | 180.0 (16.06) | 214.9 (15.98) |
| LS mean difference from placebo (95% CI) | NA | 111.7 (67.6, 155.9)** | 160.5 (116.4, 204.5)** | 146.7 (103.2, 190.2)** | 181.5 (138.1, 225.0)** |
| D28 weighted mean FEV\textsubscript{1}(0–12h), mL |         |       |       |       |       |
| n                    | 55      | 63    | 63    | 59     | 64     |
| LS mean (SE)         | −32.8 (27.03) | 34.3 (26.13) | 129.8 (26.10) | 123.4 (26.88) | 143.1 (25.42) |
| LS mean difference from placebo (95% CI) | NA | 67.1 (−4.9, 139.2) | 162.6 (90.5, 234.7)** | 156.2 (83.0, 229.4)** | 176.0 (104.3, 247.7)** |
| D28 weighted mean FEV\textsubscript{1}(0–24h), mL |         |       |       |       |       |
| n                    | 54      | 59    | 63    | 59     | 62     |
| LS mean (SE)         | −78.1 (25.46) | 3.4 (25.21) | 87.0 (24.50) | 84.1 (24.97) | 96.3 (24.13) |
| LS mean difference from placebo (95% CI) | NA | 81.5 (12.8, 150.2)* | 165.1 (97.2, 233.0)** | 162.1 (93.4, 230.8)** | 174.3 (106.5, 242.2)** |

* p = 0.02, **p < 0.001 versus placebo

Abbreviations: CI confidence interval, FEV\textsubscript{1} forced expiratory volume in 1 s, FEV\textsubscript{1}(0–6) FEV\textsubscript{1} over 0 to 6 h, FEV\textsubscript{1}(0–12) FEV\textsubscript{1} over 0 to 12 h, FEV\textsubscript{1}(0–24) FEV\textsubscript{1} over 0 to 24 h, ITT intent-to-treat, LS least squares, NA not applicable, SE standard error

*D28 trough FEV\textsubscript{1} measured on D29

---

**Fig. 2** Change from baseline in trough FEV\textsubscript{1}. a D28\textsuperscript{a} trough FEV\textsubscript{1} and b trough FEV\textsubscript{1} on D1, D15, D16 and D28. Data presented as LS mean ± SE. *p < 0.001 versus placebo. Abbreviations: FEV\textsubscript{1} forced expiratory volume in 1 s; LS least squares; Rev. revefenacin; SE standard error. *D28 trough FEV\textsubscript{1} measured on D29
Revefenacin was generally well tolerated, and the frequency of AEs was broadly comparable across all treatment groups, including placebo. Headache, shortness of breath and cough were the three most common AEs in the study (Table 4). A small number of treated subjects (five of 355) experienced worsening of COPD (four exacerbations and one worsening of symptoms) during the course of the study; these subjects were withdrawn from the study and treated appropriately.

Four SAEs were reported during the study; one in the 44 µg group (supraventricular tachycardia), two in the 175 µg group (unstable angina and hypertension) and one in the 350 µg group (intestinal obstruction). One of the four SAEs (supraventricular tachycardia) was considered by the blinded investigator to be possibly related to revefenacin, but an independent assessment by a blinded cardiologist confirmed that the condition was present during screening, the change following dosing was minimal and the likelihood of a relationship between this SAE and the study medication was low. All four SAEs resolved, but the subjects with cases of supraventricular tachycardia and unstable angina were withdrawn from the study.

AEs traditionally associated with inhaled anti-muscarinic agents were infrequent. Two incidents of dry mouth (one each in the 88 µg and 350 µg groups; both mild in severity) were observed, but no incidents of constipation, urinary retention, dysuria, blurred vision or glaucoma were reported.

Holter monitoring findings were unremarkable for changes of mean, maximum or minimum heart rates during the recording period, with no findings that were uniquely associated with revefenacin dosing or that were clearly more prominent with increasing revefenacin dose level.

**Discussion**

This study characterized the efficacy and safety of revefenacin (44, 88, 175 or 350 µg) after 28 days of once-
daily administration to patients with moderate to severe COPD. Revefenacin at doses ≥88 μg led to significant improvements in the primary endpoint (change from baseline in D28 trough FEV\textsubscript{1}). The trough FEV\textsubscript{1} improvements with the 88 and 175 μg dose (155 and 134 mL, respectively) are comparable to reported values for tiotropium bromide (126 mL) [21] delivered with the Respimat® soft mist inhaler.

As a novel once-daily LAMA, revefenacin may be differentiated from the currently available once-daily tiotropium and umeclidinium handheld products in important ways. Revefenacin’s novel biphenyl carbamate tertiary amine structure is distinct from the quaternary ammonium antagonists, [22] thus representing the first inhaled LAMA of its class to enter clinical development for COPD. The revefenacin discovery program was designed to select a 24-h–duration LAMA endowed with chemical stability (enabling long-term storage as a preservative-free aqueous solution product), high lung-to-salivary gland functional selectivity (vida infra) and a metabolically labile primary amide “soft-drug” site to allow rapid systemic clearance of the parent drug, thus potentially minimizing systemically mediated adverse events [16].

The high metabolic lability of revefenacin contrasts with the relative metabolic stability of tiotropium and its primarily renal systemic clearance profile. Instead, revefenacin shares umeclidinium’s profile of rapid metabolic turnover after distributing from the lung [23]. Systemic clearance of revefenacin is primarily via enzymatic hydrolysis versus cytochrome P450 (CYP2D6)-mediated oxidative turnover for umeclidinium [24]. Finally, the revefenacin drug product in the current study is administered via a standard jet nebulizer. This unique presentation of a once-daily bronchodilator may be of future therapeutic benefit to those patients who prefer or require nebulization therapy [9].

The sustained 24-h bronchodilator response observed previously in a 7-day study of revefenacin in patients with moderate to severe COPD [17] was supported here by the numerical similarity of trough FEV\textsubscript{1} values to the D1 and D28 weighted mean FEV\textsubscript{1} values. A sustained response was further supported by the observation of increased morning and evening PEFs throughout the treatment period, which is consistent with reports of once-daily tiotropium following 3 or 4 weeks of dosing in patients with moderate to severe COPD [21, 25]. In addition, patients treated with revefenacin used less rescue albuterol throughout the 4-week treatment period, in keeping with reduced rescue medication use reported for tiotropium [21] following 4 and 12 weeks of dosing.

Revefenacin was generally well tolerated and did not produce systemic effects typically associated with anticholinergic therapies, such as dry mouth, urinary retention, tachycardia or acute closed-angle glaucoma [26]. The incidence of dry mouth (1.4% for both 175 and 350 μg) was lower than the 4% incidence reported in a comparable 3-week study of 5 μg tiotropium administered with the Respimat soft mist inhaler in patients with COPD [25]. In addition, the revefenacin safety profile observed here was consistent with pre-clinical studies that revealed a superior lung selectivity index (ratio of anti-sialagogue to bronchoprotective potency) with inhaled revefenacin compared with either glycopyrro- nium or tiotropium [27]. Moreover, the favorable AE profile of revefenacin in this study is supported by a 7-day multiple-dose study of revefenacin (22 to 350 μg) in patients with moderate to severe COPD [17] in which the frequency of AEs was comparable across all treatment groups, including placebo.

The efficacy and safety data from this study indicate that revefenacin 88 and 175 μg represent appropriate doses for use in longer-term safety and efficacy trials. The trough FEV\textsubscript{1} data indicated that 44 μg was a subtherapeutic revefenacin dose compared with the three
Fig. 5 Effect of revefenacin on daily peak expiratory flow rate. a Morning PEF (representative of the trough PEF of the prior day’s dosing). b Evening PEF, assessed ≈12 h after daily study medication dosing. Data presented as placebo-adjusted LS mean; dotted line (---) = zero L/min; dashed line (—) represents LS mean placebo-adjusted increases in AM and PM PEF for revefenacin doses ≥88 µg, which were similar across the treatment period and centered at approximately 27 L/min and 29 L/min, respectively. Abbreviations: LS: least squares; PEFR: peak expiratory flow rate.

Table 3 Summary of mean plasma pharmacokinetic parameters

| Dose (µg) | C_{max} (ng/mL) | t_{max} (hr) | AUC_{0-24} (ng•hr/mL) | AUC_{0-t} (ng•hr/mL) | t_{1/2} (hr) |
|-----------|----------------|-------------|-----------------------|----------------------|-------------|
| 44        | 0.0203 ± 0.0124 | 0.483 (0.350, 0.500) | 0.0347 ± 0.0106 | 0.0299 ± 0.0098 | NC^b |
| n         | 7              | 7           | 4                     | 4                    | 1           |
| 88        | 0.0282 ± 0.0157 | 0.500 (0.417, 12.3^e) | 0.155 ± 0.0749 | 0.129 ± 0.0589 | NC |
| n         | 9              | 9           | 6                     | 6                    | 0           |
| 175       | 0.121 ± 0.157 | 0.517 (0.467, 0.767) | 0.351 ± 0.364 | 0.720 ± 0.864 | 51.9 ± 31.5 |
| n         | 9              | 9           | 9                     | 9                    | 5           |
| 350       | 0.146 ± 0.148 | 0.500 (0.433, 0.583) | 0.365 ± 0.306 | 0.724 ± 0.833 | 57.9 ± 31.5 |
| n         | 8              | 8           | 8                     | 8                    | 7           |

aData are mean ± SD except for t_{max} data which are median (minimum, maximum)

bT_{1/2} values were not calculated for the majority of subjects at revefenacin 44 and 88 µg due to limited data at these dose levels.

^eThe concentration observed at this t_{max} value was considered to be high compared to the rest of the subject’s profile and was reanalyzed. Reanalysis confirmed the original result, and the value was included in PK analysis.

Abbreviations: AUC_{0-24} area under the curve for plasma concentration-time from time 0 to 24 h, AUC_{0-t} area under the curve for plasma concentration-time from time 0 to the last detectable time point, C_{max} maximum plasma concentration, hr. hours, NC not calculated, PK pharmacokinetics, SD standard deviation, t_{1/2} terminal elimination half-life, t_{max} time to maximum plasma concentration.
higher doses. Additionally, the 350 \( \mu \)g dose did not demonstrate additional efficacy over that observed with 175 \( \mu \)g revefenacin. Limitations of this study include the small number of patients and the relatively short 4-week treatment period, which limit conclusions regarding the potential clinical benefits of revefenacin. However, the data from this study have informed dose selection for longer-term phase 3 clinical trials investigating the safety and efficacy of revefenacin in patients with moderate to very severe COPD. The results of those studies may reveal the potential clinical benefits of revefenacin in patients with COPD.

More broadly, certain COPD patient populations may especially benefit from the use of nebulizer therapy, such as those with chronic muscle weakness, the elderly and those with cognitive or visual impairment or diminished manual dexterity [6]. In general, these patients also prefer nebulizer therapy when hospitalized for exacerbations of COPD [23]. Currently these patients are managed with nebulized twice-daily long-acting beta-agonists (arformoterol tartrate and formoterol fumarate) or short-acting nebulized agents requiring four-times a day dosing. Revefenacin, if approved, could offer patients who require or prefer nebulized anti-muscarinic therapy the opportunity to be treated with a once-daily LAMA, as has been standard practice for many years in COPD patients who can use handheld devices containing the once-daily LAMAs (including tiotropium and umeclidinium) [22]. Additionally, revefenacin would represent the first once-daily LAMA approved for nebulized therapy, with similar efficacy to tiotropium but with less potential for anti-muscarinic side effects (eg, dry mouth) [9, 28].

**Conclusion**

Once-daily revefenacin increased trough FEV\(_1\) in patients with moderate to severe COPD, with 88 and 175 \( \mu \)g revefenacin identified as the optimal doses for use in longer-term safety and efficacy studies. Revefenacin has the potential to be the first once-daily long-acting bronchodilator for use in patients who require or prefer nebulized anti-muscarinic therapy.

**Endnotes**

1 A preliminary abstract of this study was previously published: Nicholls AJ, Barnes C, Bourdet DL, Moran EJ, Haumann B. Dose-Ranging Study Of Once-Daily TD-4208, An Inhaled Long-Acting Muscarinic Antagonist (LAMA) In Patients With Chronic Obstructive Pulmonary Disease (COPD). Am J Respir Crit Care Med. 2015;191:A5750 [Abstract].

**Abbreviations**

AE: Adverse event; AUC: Area under the curve; AUC\(_{0-24}\): AUC for plasma concentration-time from time 0 to 24 h; AUC\(_{0-\infty}\): AUC for plasma concentration-time from time 0 to the last detectable time point; CI: Confidence interval; C\(_{\text{max}}\): Maximum plasma concentration; COPD: Chronic obstructive pulmonary disease; ECG: Electrocardiogram; FEV\(_1\): Forced expiratory volume in 1 s; FEV\(_{1,0-12}\): Forced expiratory volume in 1 s over 0 to 12 h; FEV\(_{1,0-24}\): Forced expiratory volume in 1 s over 0 to 24 h; FEV\(_{1,0-6}\): Forced expiratory volume in 1 s over 0 to 6 h; ICS: Inhaled corticosteroids; ITT: Intent to treat; LABA: Long-acting beta agonist; LAMA: Long-acting muscarinic antagonist; LS: Least squares; MedDRA: Medical Dictionary for Regulatory Activities; NC: Not calculated; PEF: Peak expiratory flow; PK: Pharmacokinetic; PT: Preferred term; QTcF: Fridericia formula for QT interval correction; REV: Revefenacin; SAE: Serious adverse event; SD: Standard deviation; SE: Standard error; t\(_{1/2}\): Terminal elimination half-life; t\(_{\text{max}}\): Time to maximum plasma concentration

**Acknowledgements**

The authors wish to acknowledge Roger Hill, PhD, for medical writing and Paula Stuckart for editorial assistance in the preparation of the manuscript (Ashfield Healthcare Communications, Middletown, CT, USA).

**Funding**

This study was funded by Theravance Biopharma, Inc. (George Town, Cayman Islands), Mylan Inc. (Canonsburg, Pennsylvania, USA) and Theravance Biopharma (San Francisco, CA, USA) funded medical writing support.

**Availability of data and materials**

All authors had access to the data included in the manuscript. The datasets generated during the current study are not publicly available but can be requested from the corresponding author.

**Table 4** Treatment-emergent AEs reported in ≥1% of any treatment group (safety population)

| Patients with an AE, n (%) | Placebo (n = 71) | 44 \( \mu \)g (n = 68) | 88 \( \mu \)g (n = 71) | 175 \( \mu \)g (n = 71) | 350 \( \mu \)g (n = 74) | Total (N = 355) |
|---------------------------|-----------------|----------------------|----------------------|----------------------|----------------------|------------------|
| Any AEs                   | 22 (31.0)       | 16 (23.5)            | 26 (36.6)            | 22 (31.0)            | 23 (31.1)            | 109 (30.7)       |
| Preferred term            |                 |                      |                      |                      |                      |                  |
| Headache                  | 2 (2.8)         | 1 (1.5)              | 2 (2.8)              | 1 (1.4)              | 5 (6.8)              | 11 (3.1)         |
| Dyspnea                   | 2 (2.8)         | 0                    | 3 (4.2)              | 3 (4.2)              | 2 (2.7)              | 10 (2.8)         |
| Cough                     | 1 (1.4)         | 0                    | 0                    | 3 (4.2)              | 3 (4.1)              | 7 (2.0)          |
| COPD\(^a\)               | 2 (2.8)         | 0                    | 0                    | 1 (1.4)              | 2 (2.7)              | 5 (1.4)          |
| Back pain                 | 0               | 0                    | 1 (1.4)              | 2 (2.8)              | 1 (1.4)              | 4 (1.1)          |
| Oropharyngeal pain        | 1 (1.4)         | 1 (1.5)              | 0                    | 0                    | 2 (2.7)              | 4 (1.1)          |

\(^a\)This MedDRA PT is used in the event that a patient’s COPD worsens.

Abbreviations: AE adverse event, COPD chronic obstructive pulmonary disease, MedDRA Medical Dictionary for Regulatory Activities, PT preferred term.
Authors’ contributions
All authors contributed to the conception and design, or acquisition of data or analysis and interpretation of data; drafting the manuscript or revising it critically for important intellectual content; gave final approval of the version to be published and agreed to be accountable for all aspects of the work, ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate
The protocol and all amendments were approved by local review boards, ethics committees and health authorities at each of the 41 study centers. All patients provided written informed consent.

Consent for publication
Not applicable.

Competing interests
KP has no disclosures. CB, EM and BH are employees of the Theravance Biopharma group of companies. EK is a consultant for Amphastar, AstraZeneca, Forest, Mylan, Novartis, Sunovion, Teva and Theravance Biopharma.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Upstate Pharmaceutical Research, Greenville, SC, USA. 2Theravance Biopharma US, Inc., South San Francisco, CA, USA. 3Theravance Biopharma UK Limited, London, UK. 4Clinical Research Institute of Southern Oregon, PC, Medford, OR, USA.

Received: 15 March 2017 Accepted: 22 August 2017

Published online: 02 November 2017

References
1. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–82.
2. Barjaktarevic IZ, Amedondo AF, Cooper CB. Positioning new pharmacotherapies for COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:1427–42.
3. Montuschi P, Macagno F, Valente S, Fuso L. Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD. Curr Med Chem. 2013;20:1464–76.
4. Fuso L, Mores N, Valente S, Malerba M, Montuschi P. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem. 2013;20:1477–95.
5. Vincenzo W. Bronchodilator treatment of stable COPD: long-acting anticholinergics. Eur Respir Rev. 2005;14:23–31.
6. Bonini M, Usmani OS. The importance of inhaler devices in the treatment of COPD. COPD Res Pract. 2015;1:1–9.
7. Lavoretti F, Corrigan CJ, Barnes PJ. Retail sales of inhalation devices in European countries: so much for a global policy. Respir Med. 2011;105:1090–103.
8. Dhand R, Dolovich M, Chipp S, Myers TR, Restrepo R, Farrar JR. The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD. 2012;9:58–72.
9. Tashkin DP. A review of nebulized drug delivery in COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2585–96.
10. Quinet P, Young CA, Hentier F. The use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary disease. Ann Phys Rehabil Med. 2010;53:69–76.
11. Maher DA, Waterman LA, Ward J, Gifford AH. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. J Aerosol Med Pulm Drug Deliv. 2014;27:103–9.
12. Sulaman I, Gushen B, Greene G, et al. Objective assessment of adherence to inhaled COPD patients. Am J Respir Crit Care Med. 2017;195:1333–43.
13. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines. American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127:335–71.
14. Pudi K, Pendyala S, Barnes C, Moran E, Haumann B, Kenwin E. Trials in progress: two 12-week, randomized, double-blind, placebo-controlled, parallel-group phase 3 trials of a nebulized long-acting muscarinic antagonist (revefenacin) in study participants with moderate to very severe COPD. Chest. 2016;150:825A. [Abstract]
15. DelaCruz L, Pendyala S, James C, Moran E, Haumann B, Feldman G. Trial in progress: a 52-week, randomized, double-blind, placebo-controlled, parallel-group phase 3 trial to evaluate the safety and tolerability of a nebulized long-acting muscarinic antagonist (revefenacin) in study participants with COPD. Chest. 2016;150:866A. [Abstract]
16. J. Y. Husfeld C, Pulido-Rios MT, et al. Duration by design: discovery of Revefenacin, the first-in-class Nebulized once-daily bronchodilator for the treatment of patients with COPD. Chest. 2016;150:970A. [Abstract]
17. Nicholls A, Barnes C, Yates W, Moran E, Singh D. A randomized, crossover, 7-day study of once-daily TD-4208, a long-acting muscarinic antagonist, in subjects with COPD. Am J Respir Crit Care Med. 2014;189:A6003. [Abstract]
18. ICH. Integrated addendum to ICH harmonised guideline: guideline for good clinical practice E6 (R2). https://goo.gl/CF0mR3. Accessed 20 Jul 2017.
19. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191-2194.
20. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.
21. van Noord JA, Cornelissen PJ, Aurnink J, Platz J, Mueller A, Fogarty C. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med. 2000;103:22–9.
22. Montuschi P, Gabattioni G. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. J Med Chem. 2013;58:1431-64.
23. Babu KS, Mohammed J. Nebulised therapy in the management of COPD: evidence and we will help you at every step:
Submit your next manuscript to BioMed Central and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research
Submit your manuscript at www.biomedcentral.com/submit...